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E-mail: guangping.gao@umassmed.eduImproper activity of bone-resorbing osteoclasts results in low
bone density and deterioration of bone structure, which in-
crease the risk of fractures. Anti-resorptive therapies targeting
osteoclasts have proven effective in preserving bone mass, but
these therapeutic agents lead to defective new bone formation
and numerous potential side effects. In this study, we demon-
strate that recombinant adeno-associated virus, serotype 9
(rAAV9) can deliver to osteoclasts an artificial microRNA
(amiR) that silences expression of key osteoclast regulators,
RANK (receptor activator for nuclear factor kB) and cathepsin
K (rAAV9.amiR-rank, rAAV9.amiR-ctsk), to prevent bone loss
in osteoporosis. As rAAV9 is highly effective for the transduc-
tion of osteoclasts, systemic administration of rAAV9 carrying
amiR-rank or amiR-ctsk results in a significant increase of bone
mass in mice. Furthermore, the bone-targeting peptide motif
(Asp)14 or (AspSerSer)6 was grafted onto the AAV9-VP2 capsid
protein, resulting in significant reduction of transgene expres-
sion in non-bone peripheral organs. Finally, systemic delivery
of bone-targeting rAAV9.amiR-ctsk counteracts bone loss
and improves bone mechanical properties in mouse models
of postmenopausal and senile osteoporosis. Collectively, inhi-
bition of osteoclast-mediated bone resorption via bone-target-
ing rAAV9-mediated silencing of ctsk is a promising gene
therapy that can preserve bone formation and mitigate osteo-
porosis, while limiting adverse off-target effects.
INTRODUCTION
Osteoporosis is an aging-associated disease marked by bone loss and
deterioration of the bone microstructure.1 Collectively, these factors
significantly increase the risk of fractures. Most existing therapeutic
agents for osteoporosis are anti-resorptive agents, such as bisphosph-
onates and anti-RANKL (receptor activator of nuclear factor kB
ligand) antibody, inhibitors of osteoclast (OC) differentiation and
bone resorption. Unfortunately, their effectiveness is limited by an
inability to promote new bone formation, as OC-mediated bone
resorption is coupled with osteoblast-mediated bone formation dur-
ing remodeling.2,3 Moreover, these agents are accompanied by poten-
tial adverse effects, including atypical fractures and osteonecrosis of922 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2
This is an open access article under the CC BY license (http://creatithe jaw.4,5 Thus, the development of anti-resorptive therapies that
can preserve osteoblast function while limiting off-target side effects
is still an unmet need.
OCs originate from hematopoietic stem cells (HSCs) in the
bone marrow and require macrophage-colony stimulating factor
(M-CSF) and RANKL for the differentiation of monocytes to multi-
nucleated OCs. The loss of M-CSF and its receptor c-Fms,6 or
RANKL and its receptor RANK,7,8 results in severe osteopetrosis
and abnormal tooth eruption in mice because of a complete absence
of mature OCs. Osteoprotegerin (OPG), a soluble decoy receptor for
RANKL, acts as a natural suppressor of RANKL-RANK signaling by
obstructing RANKL binding to RANK on the surface of OC precursor
cells.9 Similarly, the human monoclonal immunoglobulin G (IgG)2
antibody against RANKL (denosumab) prevents RANKL from acti-
vating RANK, thereby inhibiting OC survival and differentiation.10
Despite its favorable therapeutic efficacy and safety profile, contin-
uous treatment with denosumab reduces physiologic bone remodel-
ing and causes potential adverse effects.3
Cathepsin K (CTSK), a cysteine protease member of the cathepsin
lysosomal protease family, is highly expressed in OCs and efficiently
degrades type 1 collagen, the major component of organic bone ma-
trix.11 Mice lacking CTSK display osteopetrosis as a consequence of
impaired bone resorption, while bone formation is normal or
increased.12,13 In human clinical trials, the pharmacologic CTSK in-
hibitor odanacatib showed a continuous increase in bone mineral
density and enhanced bone strength at the hip and spine. However,
as CTSK is expressed in various nonskeletal tissues, including skin,






Figure 1. rAAV9 Transduces Osteoclast Lineage Cells In Vitro and In Vivo
(A–D) A single dose of PBS or 8 1011 genome copies (GC) of rAAV.EGFP was intravenously (i.v.) injected into 2-month-old male mice, and EGFP expression was assessed
in cryosectioned femurs by fluorescence microscopy 2 weeks post-injection. (A) Arrow indicates megakaryocytes with autofluorescence. TB, trabecular bone; BM, bone
marrow; GP, growth plate (n = 3/group). Scale bars, 100 mm. (B) Cells were also immunostainedwith anti-CTSK antibody to identify osteoclast (OC)-lineage cells. Arrowheads
(legend continued on next page)
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dents.14–16
Adeno-associated virus (AAV), a small non-enveloped parvovirus
with a single-stranded genome, has been used for gene therapy in
more 140 clinical trials, involvingmore than 2,000 patients worldwide.
Recombinant AAVs (rAAVs) show high transduction efficiency,
persistent transgene expression, and generally lack post-infection
immunogenicity and pathogenicity.17–19 The AAV vector genome
contains two inverted terminal repeats (ITRs) and regulatory (rep)
and structural capsid (cap) open reading frames (ORFs). A transgene
of interest can replace the rep and capORFs, producing a replication-
defective rAAV genome.20,21 Additionally, self-complementary AAV
(scAAV) vectors were developed to enhance in vitro and in vivo trans-
duction efficacies.22–25 Using a bone-targeting AAV9 capsid, this
study aimed to develop an osteoporosis therapy that simultaneously
suppresses OC-mediated bone resorption and promotes osteoblast-
mediated bone formation, while limiting off-target side effects. We
provide a proof-of-concept demonstration that a rationally designed
AAV9 capsid can deliver an artificial microRNA (amiR) that silences
the expression of RANK (OC survival/differentiation) or CTSK (OC
resorption activity) in OCs to reverse bone loss and improve boneme-
chanical properties in mouse models of postmenopausal and senile
osteoporosis, while detargeting transduction to non-relevant tissues.
RESULTS
rAAV9 Can Effectively Transduce OCs
Our previous study demonstrated that systemic delivery of rAAV9 in
mice can transduce osteoblast-lineage cells and OCs residing on the
bone surface (BS).26 Since OCs originate from HSCs in the bone
marrow, we explored the ability of rAAV9 to transduce other HSC-
lineage cells. rAAV9.EGFP was intravenously (i.v.) injected into
2-month-old mice and the tissue distribution of rAAV9 was assessed
by EGFP expression using IVIS (in vivo imaging system) optical im-
aging (Figure S1). Individual organ imaging of treated mice showed
EGFP expression in the heart, liver, and hindlimbs. In the femur,
most EGFP-expressing cells, including osteoblasts and CTSK-ex-
pressing OCs, were located in the trabecular bone of the metaphysis,
while only a few round-shaped bone marrow cells exhibited EGFP
expression (Figures 1A and 1B). Flow cytometry analysis of boneindicate AAV9-transduced CTSK+ OCs. Scale bar, 75 mm. (C and D) Alternatively, EGFP
gating strategy of OC precursors (OCPs; CD3ε, B220, TER119, CD11b/lo, Ly6c+)
are displayed in the dot plot and histogram, respectively. (E) Bone marrow-derived mo
colony-stimulating factor) for 6 days to differentiate into bone marrow-derived macropha
used to treat BMMs at day 0, or BMDMs and BMDCs at day 6, of culturing. Transduction
nuclei were stained by DAPI. Scale bars, 1 mm. Alternatively, BMMs were cultured with
respectively. rAAV9.EGFP was used to treat pre-OCs at day 2 or mature OCs at day 6 o
OCs were transduced with either rAAV9 carrying EGFP control (rAAV9.vec) or Cre recom
mRNA and (G) TRAP activity were measured by RT-PCR (F) and colorimetric assay (G, le
1 mm. (H–J) A single dose of 8  1011 GC of rAAV9.vec or rAAV9.cre was i.v. injecte
performed on cryosectioned femurs to identify EGFP-expressing cells 2 weeks post-in
post-injection. Representative 3D reconstruction (I) and relative quantification (J) are
(Tb.Th), trabecular number per cubic millimeter (Tb.N), and cortical thickness (Cort.Th) a
***p < 0.001 ****p < 0.0001 by an unpaired two-tailed Student’s t test.
924 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2marrow cells confirms EGFP expression in a small subset of
CD11b+ monocytes, OC progenitors (OCPs; CD3ε, B220,
TER119, CD11b/lo, Ly6c+), and B220+ B lymphocytes (Figures
1C and 1D; Figures S2B and S2C). Of note, megakaryocytes residing
in the bone marrow display autofluorescence (Figure 1A, right; Fig-
ure S2A). An in vitro differentiation assay of bone marrow-derived
monocytes (BMMs) revealed that rAAV9 is highly effective for trans-
ducing RANKL-treated pre-OCs and mature OCs, but not BMMs,
bone marrow-derived macrophages (BMDMs), and bone marrow-
derived dendritic cells (BMDCs) (Figure 1E). Thus, these results
demonstrate that rAAV9 is more effective in transducing pre-OCs
and mature OCs than other HSC-lineage cells in the bone marrow.
RANK is a member of tumor necrosis factor receptor (TNFR) family
essential for the differentiation of monocytes to mature OCs.27
Accordingly, conditional deletion of a floxed rank allele with Cre de-
leter mice targeting OCs (Rankfl/fl;Ctsk) results in osteopetrosis,
because of a lack of OC-mediated bone resorption (Figures S3A and
S3B). To provide a proof-of-concept demonstration that systemically
delivered rAAV9 can target Rank in OCs to inhibit bone resorption,
we generated an rAAV9 vector expressing Cre recombinase (rAAV9.-
Cre, Figure S3C), which mediates the deletion of Rank in OC lineage
cells. rAAV9-mediated Cre expression in cultured Rankfl/fl pre-OCs
was effective in deletingRank and ablatingOCdifferentiation (Figures
1E and 1F). To visualize rAAV9-mediated Cre expression in OCs
in vivo, the Cre-reporter RosamT/mG mice were crossed with Rankfl/fl
mice (Rankfl/fl;RosamT/mG). rAAV9.Cre was i.v. injected into 2-
month-old Rankfl/fl;RosamT/mG mice, and Cre-mediated GFP expres-
sion in the femur was validated by fluorescence microscopy 2 weeks
post-injection (Figure 1G). Two months after the injection, rAAV9.-
Cre-treated femurs showed a significant increase in trabecular bone
mass and cortical thickness relative to rAAV9.EGFP-treated femurs
(Figures 1H and 1I). These results demonstrate that systemically deliv-
ered rAAV9.Cre in Rankfl/fl;RosamT/mG mice targets OCs and directs
the deletion of Rank to increase bone mass.
rAAV9-Mediated Gene Silencing in OCs Increases Bone Mass in
Mice
To inhibit OC-mediated bone resorption, we aimed to silence
key OC regulators, RANK (tnfrsf11a) and CTSK (ctsk), usingexpression in bone marrow cells was assessed by flow cytometry. Flow cytometry
is described in Figure S2C. GFP-expressing, CD11b-positive cells (C) and OCPs (D)
nocytes (BMMs) were cultured with M-CSF or GM-CSF (granulocyte-macrophage
ges (BMDMs) or dendritic cells (BMDCs), respectively. 1011 GC of rAAV9.EGFPwere
efficiencies were assessed by EGFP expression using fluorescencemicroscopy. Cell
M-CSF and RANKL for 2 and 6 days to differentiate into pre-OCs and mature OCs,
f culturing. (F and G) Two days after treatment with M-CSF and RANKL, Rankfl/fl pre-
binase (rAAV9.Cre) and then differentiated into mature OCs. Levels of (F) cre or rank
ft). Representative images of TRAP-stained OCs are displayed (G, right). Scale bars,
d into 3-month-old female Rankfl/fl;RosamTmG mice. Fluorescence microscopy was
jection (H), and femoral trabecular bone mass was assessed by microCT 2 months
displayed. Trabecular bone volume/total volume (Tb.BV/TV), trabecular thickness








Figure 2. rAAV9-Mediated Gene Silencing in OCs Increases Bone Mass in Mice
(A) Diagram of the rAAV9 constructs containing a CMV (cytomegalovirus) enhancer/chicken b-actin promoter (CB), amiR-ctrl, amiR-rank, or amiR-ctsk, an EGFP reporte
gene, b-globin poly(A) sequence (PA), and inverted terminal repeats (ITRs). (B and C) Two days after treatment with M-CSF and RANKL, wild-type pre-OCs were transduced
with either rAAV9 carrying amiR-ctrl, amiR-rank, or amiR-ctsk (1011 GC) and then differentiated into mature OCs. (B) Levels of rank or ctskmRNAwere measured by RT-PCR
(legend continued on next page
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small silencing RNA into the miR-33-derived miRNA scaffold
(amiR) limits short hairpin RNA (shRNA)-related toxicity, enables
efficient gene knockdown, and reduces off-target silencing by 10-
fold compared to conventional shRNA constructs.28 We therefore
generated amiR cassettes targeting two different positions of rank
(amiR-rank) or ctsk (amiR-ctsk) mRNA and then packaged them
with AAV9 capsids (Figure 2A). Of note, the amiR cassette is
embedded within the EGFP intronic region of the transgene cassette
to track transduced cells or tissues. The knockdown efficiency of these
vectors in cultured wild-type pre-OCs was examined using RT-PCR
(Figure 2B; Figures S4A–S4D). We found that the levels of rank or
ctsk mRNA were more efficiently reduced in the cells when treated
with rAAV9.amiR-rank-2 or amiR-ctsk-1 than rAAV9.amiR-rank-1
or amiR-ctsk-2 (Figures S4B and 4SD). Hereafter and in Figure 2,
amiR-rank-2 and amiR-ctsk-1 are referred to as amiR-rank and
amiR-ctsk, respectively.
Genetic deletion of rank in mice results in a complete absence of
OCs due to defective OC survival and differentiation.7,8 In contrast,
loss of CTSK impairs OC resorption activity while preserving OC
survival and differentiation.12,13 Similar to the genetic deletion of
rank or ctsk, rAAV9-mediated silencing of rank impairs both OC
differentiation and resorption activity, whereas only bone resorption
activity was markedly reduced in rAAV9.amiR-ctsk-treated cells
(Figure 2C). To examine the ability of amiR-rank or amiR-ctsk
to inhibit bone resorption in vivo, rAAV9 vectors carrying either
transgenes were i.v. injected into 2-month-old mice, and two
months later, whole-body and femur EGFP expression was visual-
ized by IVIS imaging (Figure S4E) and fluorescence microscopy
(Figure 2D), respectively. Compared to rAAV9.amiR-ctrl-treated fe-
murs, rAAV9.amiR-rank- or amiR-ctsk-treated femurs displayed
~60% reduction of rank or ctsk mRNA levels and a relative
increase in trabecular bone mass (Figures 2F and 2G). Intriguingly,
rAAV9.amiR-ctsk demonstrates a higher potency of bone accrual
than does rAAV9.amiR-rank, as shown by the greater trabecular
bone volume (BV), number, and thickness in rAAV9.amiR-ctsk-
treated femurs relative to rAAV9.amiR-rank-treated femurs. To
gain insight into the mechanism of these findings, histomorphome-
try was performed in the metaphysis of treated femurs to assess
in vivo OC and osteoblast activities. In rAAV9.amiR-rank-
treated femurs, the numbers of tartrate-resistant acid phosphatase
(TRAP)-positive OCs and bone erosion surfaces were markedly
reduced, compared to rAAV9.amiR-ctrl-treated femurs (Figures
3A and 3C). However, treatment with rAAV9.amiR-ctsk results in
a significant reduction in bone erosion surfaces where flat-
shaped OCs reside, while OC numbers were not significantly alteredand normalized to hprt. (C) Transduction efficiency, OC differentiation, and resorption a
respectively. Representative images of TRAP-stained OCs and resorption pit are displa
carrying amiR-ctrl, amiR-rank, or amiR-ctskwas i.v. injected into 2-month-old female mic
of rank or ctsk in the tibia were assessed by fluorescence microscopy (D) and RT-PC
microCT. Representative 3D-reconstruction (F) and relative quantification (G) are display
0.01, ****p < 0.0001 by an unpaired two-tailed Student’s t test and one-way ANOVA t
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bone formation rate (BFR), mineral apposition rate (MAR), and
osteoblast surface per BS (Ob.S/BS) were markedly increased in
rAAV9.amiR-ctsk-treated femurs (Figures 3F–3H). These findings
demonstrate that treatment with rAAV9.amiR-rank results in a sig-
nificant decrease in OC differentiation and resorption activity
without any alteration in osteoblast activity. Alternatively, treatment
with rAAV9.amiR-ctsk simultaneously impairs OC-mediated bone
resorption and promotes osteoblast-mediated bone formation,
without affecting OC differentiation. Notably, treatment of cultured
osteoblasts with rAAV9.amiR-ctsk did not affect osteoblast prolifer-
ation and differentiation (Figure S5), demonstrating that increased
osteoblast activity seen in rAAV9.amiR-ctsk-treated femurs is an in-
direct effect of rAAV9-mediated silencing of ctsk. Instead, similar to
mice a with genetic deletion of ctsk in OCs,29 rAAV9.amiR-ctsk-
treated femurs display elevated levels of sphingosine kinase 1
(sphk1) and runt related transcription factor 2 (runx2) mRNA (Fig-
ure 3I). Given that SPHK1 promotes osteogenesis by phosphory-
lating sphingosine to generate sphingosine 1 phosphate (S1P),30
rAAV9-mediated silencing of ctsk in OCs likely enhances osteo-
blast-mediated bone formation via increased production of S1P.
Taken together, the rAAV9-amiR-ctsk vector is a more potent agent
for osteoporosis therapy than the rAAV9-amiR-rank vector, since
amiR-ctsk can suppress OC-mediated bone resorption and promote
osteoblast-mediated bone formation, simultaneously.
Development of a rAAV9 Capsid Targeting OCs in the Bone
Tissue
Expression of CTSK is also seen in various non-skeletal tissues,
including epidermal, cardiovascular, and cerebrovascular sites.
Therefore, pharmacologic inhibition of CTSK causes an increased
risk of off-target cerebrovascular accidents in clinical trials.14–16
Thus, we aimed to detarget the transduction of rAAV9 to non-skeletal
tissues by utilizing a bone-homing capsid. Previously reported pep-
tide motifs that can direct a liposome to osteoblast-enriched bone-
forming surfaces, (Asp-Ser-Ser)6,
31 or OC-enriched bone-resorbing
surfaces, (Asp)14,
32 were grafted onto the N terminus of the VP2 sub-
unit of the AAV9 capsid protein26 (Figure 4A). Since hydroxyapatite
(HA) is a major inorganic component in the bone tissue,33 we tested
the capsid for HA-binding affinity in vitro. Genome copies (GC) of
AAV9.DSS-Nter (rAAV9.DSS) and AAV9.D14-Nter (rAAV9.D14)
in the HA pellet were markedly increased relative to those of
rAAV9 (Figure 4B, left), while GC of these vectors in the supernatant
were decreased (Figure 4B, right), demonstrating that both of the
AAV9.DSS-Nter and AAV9.D14-Nter capsids can enhance HA-
binding affinity. Of note, capsid grafting of these motifs did not affect
rAAV9’s transduction efficiency in OCs (Figure 4C). To test thectivity were assessed by EGFP expression, TRAP staining, and resorption pit assay,
yed (n = 4/group). Scale bars, 1 mm. (D–G) A single dose of 8  1011 GC of rAAV9
e. Two months later, EGFP expression in the cryosectioned femur and mRNA levels
R (E), respectively (n = 8/group). Femoral trabecular bone mass was assessed by








Figure 3. rAAV9-Mediated Gene Silencing in OCs Inhibits Bone Resorption in Mice
A single dose of 8 1011 GC of rAAV9 carrying amiR-ctrl, amiR-rank, or amiR-ctsk was i.v. injected into 2-month-old female mice. Two months later, histomorphometry was
performed in the metaphysis of treated femurs to assess in vivo OC and osteoblast activities. (A–H) Quantification of OC.S/BS, ES/BS (C and D), BFR/BS, MAR (F and G),
OB.S/BS (H), and representative TRAP-stained femurs (A and B) and calcein/alizarin red-labeled femurs (E) are displayed (n = 8/group). Arrows indicate OCs residing on the
bone surface (B, right) and the distance between calcein and alizarin red labeling (E). (I) mRNA levels of runx2 or sphk1 in the tibia were assessed by RT-PCR. OC.S/BS,
osteoclast surface/bone surface. ES/BS, erosion surface/bone surface; BFR/BS, bone formation rate/bone surface; MAR, mineral apposition rate; OB.S/BS, osteoblast
surface/bone surface. Scale bars, A and B (left), 100 mm; B (right) and E, 50 mm. Values represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by an
unpaired two-tailed Student’s t test and one-way ANOVA test. N.S., not significant.
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Figure 4. Development of a Bone-Homing rAAaV9 Capsid
(A) Diagram of constructs for the rationally designed bone-homing rAAV9 capsids. The bone-targeting-peptide motifs ((DSS)6, blue; D14, red) were inserted into the AAV9
capsid at the N terminus of AAV9-VP2 (AAV9.DSS-Nter, AAV9.D14-Nter). cap, capsid proteins. (B) Hydroxyapatite (HA)-binding assay. Vectors (109 GC) were incubated with
HA beads for 1 h at 37C and pelleted by centrifugation at 300 rpm. Vector titers in the pellet and supernatant were measured by ddPCR and normalized to PBS control. (C)
Two days after treatment with M-CSF and RANKL, wild-type pre-OCs were transduced with vectors (1011 GC) and then differentiated into mature OCs. Transduction ef-
ficiency was assessed by EGFP expression using fluorescence microscopy. Scale bars, 1 mm. (D–F) A single dose of 8 1011 GC of vectors was i.v. injected into 2-month-
old female mice, and 2 weeks later, EGFP expression in individual tissues was assessed by IVIS 100 optical imaging. (D and E) Representative tissues (D) and relative
quantification (E) are displayed (n = 3/group). Scale bars represent relative fluorescence (p/s/cm2/sr/mW/cm2). (F) Alternatively, EGFP expression was assessed by fluo-
rescence microscopy in cryosectioned brain, heart, liver, skeletal muscle, and femur. Boxes indicate areas of high magnification images displayed in Figure S6B. Scale bars,
100 mm. Values represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by an unpaired two-tailed Student’s t test and one-way ANOVA test. N.S., not
significant.
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into 2-month-old mice and vector biodistributions were assessed by
EGFP expression using IVIS optical imaging 2 weeks post-injection
(Figures 4D and 4E; Figure S6A). rAAV9.DSS-Nter-treated mice ex-
hibited less EGFP expression than that achieved by rAAV9 in the liver
(~50% less) and muscle (~30% less), and little to no expression in the
heart. However, the biodistributions of rAAV9.D14-Nter were com-
parable to those of rAAV9, suggesting that the AAV9.D14-Nter
capsid is unable to confer bone-homing specificity of rAAV9 in vivo.
These results are consistent with fluorescence microscopy data
showing a nearly complete lack of EGFP expression in the heart
and a significant reduction in the liver and muscle of rAAV9.DSS-
Nter-treated mice when compared with mice treated with rAAV9
or rAAV9.D14-Nter (Figure 4F; Figure S6B). Importantly, expression
in femurs was relatively comparable between treatment groups (Fig-
ures 4D and 4F), demonstrating that the AAV9.DSS-Nter capsid, not
the AAV9.D14-Nter capsid, reduces transduction from non-skeletal
tissues. Likewise, GC of AAV9.DSS-Nter in the liver were markedly
decreased relative to those of rAAV9, whereas GC of these vectors
in the bone were relatively comparable (Figure S6C). We note that
with the doses of vector used in these experiments (8  1011 GC/
mouse), we did not anticipate strong transduction of brain tissues
following i.v. administration (Figure 4F). Taken together, the DSS-
VP2 capsid protein, not the D14-VP2 capsid protein, improves
bone-homing specificity of rAAV9 by detargeting its transduction
to non-relevant tissues.
Bone-targeting rAAV9-Mediated Silencing of ctsk Counteracts
Bone Loss in Mouse Models of Osteoporosis
Postmenopausal (type 1) and senile (type 2) osteoporosis results in se-
vere bone loss and deterioration of bone structure, increasing the risk
of fractures. Bone loss in postmenopausal women is caused by
enhanced OC activity as a result of estrogen withdrawal. Estrogen,
which is normally produced as a part of the menstrual cycle, mainly
acts on OCs as a negative regulator, preventing OC-mediated bone
resorption.34 Senile osteoporosis typically develops after the age of
70 for bothmen and women, and is a consequence of bone senescence
and calcium deficiency. To test therapeutic effects of our bone-target-
ing rAAV9-mediated gene silencing in osteoporosis, we packaged
amiR-ctsk with AAV9.DSS-Nter capsid. Compared to rAAV9.a-
miR-ctsk, the rAAV9.DSS-amiR-ctsk showed a modest reduction in
infectivity at lower doses (5  1010 GC/kg) (Figure S7A), but effec-
tively silenced expression of ctsk (Figure S7B) and inhibited OC
resorption activity (Figure S7C) without any alteration in TRAP ac-
tivity at a dose of 5  1012 GC/kg. These results demonstrate thatFigure 5. Bone-Targeting AAV9-Mediated Silencing of ctsk Reverses Bone Los
(A) Timeline of the study and treatment methods. (B–J) Sham or OVX surgery was perfo
rAAV9.DSS-Nter carrying amiR-ctrl or amiR-ctsk was i.v. injected. (B) Seven weeks aft
trabecular bone mass was assessed by microCT. (C and D) Representative 3D recon
tomorphometric quantification of ES/BS, N.OC/T.Ar (E), representative calcein/alizarin r
sphk1 mRNA levels in the tibia were assessed by RT-PCR and normalized to hprt (n =
apparent bending stress, and work to bending moment were quantified (n = 7/group). V
unpaired two-tailed Student’s t test and one-way ANOVA test. N.S., not significant.
930 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2there are no adverse effects of the AAV9.DSS-Nter capsid on the ther-
apeutic potential of amiR-ctsk.
Ovariectomized (OVX) mice are an established model for postmeno-
pausal osteoporosis induced by estrogen deficiency.35 Sham or OVX
surgery was conducted on 3-month-old female mice and
rAAV9.DSS-amiR-ctsk was i.v. injected 6 weeks post-surgery (Fig-
ure 5A). Seven weeks after injection, reduced levels of ctsk mRNAs
were validated in amiR-ctsk-expressing OVX femurs (Figure 5B).
While amiR-ctrl-expressing OVX mice showed a significant reduc-
tion in trabecular bone mass relative to sham mice, bone loss was
completely reversed in the femurs of amiR-ctsk-expressing OVX
mice, as demonstrated by the greater trabecular BV/total volume
(TV), thickness, number, and connectivity density (Figures 5C and
5D). These femurs displayed a decrease in bone erosion surfaces (Fig-
ure 5E, left), while the number of OCs in the total bone area is rela-
tively comparable to that of amiR-ctrl-expressing OVX femurs (Fig-
ure 5E, right). Additionally, treatment with rAAV9.DSS-amiR-ctsk
in OVX mice enhances BFR, MAR, and Ob.S/BS (Figures 5F–5H),
which is accompaniedwith elevated levels of sphk1mRNA (Figure 5I).
This effect is specific to the bone tissue, as no mineralization was de-
tected in non-skeletal tissues, including brain, heart, liver, and skeletal
muscle (Figure S8). Finally, biomechanical testing analysis showed
that the strength and stiffness of femurs were considerably protected
from OVX-induced bone loss when treated with rAAV9.DSS-amiR-
ctsk (Figure 5J), suggesting that bone-targeting rAAV9-mediated
silencing of ctsk improves clinically meaningful endpoints in osteopo-
rotic mice. Taken together, these results demonstrate that systemic
delivery of amiR-ctsk by the bone-tropic capsid can counteract
bone loss and enhance clinically relevant mechanical properties of
bone after the onset of estrogen deficiency-induced osteoporosis by
simultaneously suppressing OC-mediated bone resorption and pro-
moting osteoblast-mediated bone formation.
Next, we tested therapeutic effects of rAAV9.DSS-amiR-ctsk in a
mouse model of senile osteoporosis. Vector was i.v. injected into
18-month-old male mice and 2 months later, EGFP expression in fe-
murs and lumbar vertebrae was assessed by fluorescence microscopy
(Figure 6A). EGFP-expressing cells are mainly located on the surface
of trabecular bones in femurs and vertebrae. Compared to amiR-ctrl-
treated animals, mice injected with amiR-ctsk showed reduced levels
of ctsk mRNA (Figure 6B) and a relative increase in trabecular bone
mass within the femur and lumbar vertebrae, as indicated by greater
trabecular BV/TV, thickness, and number (Figures 6C–6F). As higher
expression of EGFP is detected in femurs relative to vertebrae, bones in a Mouse Model of Postmenopausal Osteoporosis
rmed on 3-month-old female mice. Six weeks later, a single dose of 8  1011 GC of
er injection, ctsk mRNA levels were assessed in the tibia (B, n = 8/group). Femoral
struction (D) and relative quantifications (C) are displayed (n = 8/group). (E–H) His-
ed labeling (F), BFR/BS, MAR (G), and OB.S/BS (H) are displayed (n = 8–9/group). (I)
8). (J) Femoral biomechanical properties, including bending rigidity and moment,






Figure 6. Bone-Targeting AAV9-Mediated Silencing of ctsk Prevents Bone Loss in a Mouse Model of Senile Osteoporosis
A single dose of 8  1011 GC of rAAV9.DSS carrying amiR-ctrl or amiR-ctsk was i.v. injected into 18-month-old male mice. (A) Two months later, EGFP expression in
cryosectioned femurs and lumbar vertebrae (L4) were assessed by fluorescence microscopy. (B) Levels of ctskmRNA in the tibia were assessed by RT-PCR (n = 6/group).
Trabecular bone mass and cortical thickness in femurs and lumbar vertebrae (L4) were assessed by microCT. (C–F) Representative 3D-reconstruction (C and E) and relative
quantification (D and F) are displayed (n = 6/group). Scale bars, 500 mm. Values represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 by an unpaired two-tailed Student’s t
test and one-way ANOVA test. N.S., not significant.
www.moleculartherapy.orgaccrual in femurs was greater than in vertebrae of mice treated with
rAA9.DSS.amiR-ctsk. Thus, these results demonstrate that bone-tar-
geted delivery of amiR-ctsk is also effective at reversing bone loss in
senile osteoporosis. Collectively, rAAV9.DSS-amiR-ctsk is a prom-
ising therapeutic agent for both postmenopausal and senile
osteoporosis.
DISCUSSION
Our previous study demonstrated that bone-targeting rAAV9-medi-
ated silencing of Schnurri-3 in osteoblasts is a bone-anabolic therapy
for osteoporosis that does not alter OC development. This study
establishes a promising osteoporosis therapy that simultaneously sup-
presses OC-mediated bone resorption and promotes osteoblast-
mediated bone formation, while limiting adverse off-target effects.
In addition to osteoblasts, AAV9 targets OCs to drive RNAi-mediated
silencing of the key OC regulators RANK and CTSK, which we showMoleculhave clinical relevance as genetic targets to prevent osteoporosis.
Since rAAV9 can transduce both osteoblasts and OCs in vivo,26 our
OC-targeting rAAV9-based gene therapy can complement our previ-
ous approach, which only targeted osteoblasts for the treatment of
osteoporosis.
Unlike other RNAi-based strategies using liposomes31 or lipid-based
nanoparticles,36 a single systemic injection of rAAV9.DSS.amiR-ctsk
is sufficient to increase bone accrual in mice. Due to their high-trans-
duction efficiency, ability to confer persistent transgene expression,
and lack of post-infection immunogenicity and pathogenicity, AAV
vectors have a long track record for safety and efficacy in relevant pre-
clinical and clinical studies.37 In particular, rAAV9-mediated gene
therapy is currently the leading platform for the treatment of neuro-
logical disorders,38 as systemically delivered rAAV9 can traverse the
blood-brain barrier to target the central nervous system (CNS).39ar Therapy: Methods & Clinical Development Vol. 17 June 2020 931
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ability to transduce various peripheral tissues, such as liver, retina,
striated muscles, and bone in adult mice.26,40,41 rAAV9 is likely to
be effective for the transduction of osteoblasts and OCs that reside
in the trabecular bone of femur with high bone remodeling activity
relative to lumbar vertebrae. This is accompanied with greater bone
accrual in femurs relative to vertebrae when treated with rAAV9.a-
miR-ctsk. Notably, treatment with rAAV9.amiR-ctsk results in
impaired bone resorption activity and elevated expression of sphk1,
which produces S1P to promote differentiation of neighboring
RUNX2+ osteoblasts. Therefore, bone-targeting rAAV9-mediated
silencing of ctsk in OCs is a potent gene therapy to treat osteoporosis,
while limiting adverse off-target effects.
RANK and CTSK are promising therapeutic targets for osteoporosis.
Denosumab, the human monoclonal IgG2 antibody against
RANKL,10 and odanacatib, the pharmacologic CTSK inhibitor,14
are both effective in preventing bone loss in human patients with oste-
oporosis. However, continuous treatment with denosumab reduces
physiologic bone remodeling and can potentially be accompanied
by adverse effects.3 Furthermore, pharmacological inhibition of
CTSK causes off-target cerebrovascular accidents.16 It was therefore
apparent that the safety of rAAV9 in the brain be considered. Two
bone-homing peptide motifs, (Asp-Ser-Ser)6
31 and (Asp)14,
32 have
been developed to direct liposomes to osteoblast-enriched bone-
forming and OC-enriched bone-resorbing surfaces, respectively.
Therefore, display of the (Asp)14 peptide on the capsid protein may
enhance rAAV9’s ability to transduce OCs in vivo. To address this,
we rationally designed an AAV9 capsid by grafting the peptide motif
(Asp)14 or (Asp-Ser-Ser)6 onto AA9-VP2. Although both
AAV9.D14-Nter and AAV9.DSS-Nter capsids enhance in vitro
HA-binding affinity, only the AAV9.DSS-Nter capsid can detarget
transduction from non-skeletal tissues in mice, while retaining trans-
duction in OCs and osteoblast-lineage cells26 that reside on the BS.
This capability demonstrates its ability to specifically target both
OC-enriched bone-resorbing areas and osteoblast-enriched bone-
forming areas. We note that the transduction efficiencies of rAAVs
in vitro are scarcely predictive of their in vivo performance. This phe-
nomenon may be due to the presence of multiple physiological bar-
riers related to the route of administration, serum factors, circulating
neutralizing antibodies, and extracellular barriers.42 Future vector im-
provements to transduce exclusively OC lineage cells, such as using
OC-specific promoters in the vector genome design or further engi-
neering of capsids, will allow for even more precise bone-targeting
rAAV vectors to be developed. Finally, the bone-targeted, rAAV9-
mediated silencing of ctsk in OCsmay have clinical utility for counter-
acting bone loss in other skeletal diseases, such as inflammatory
arthritis-induced bone loss.
MATERIALS AND METHODS
rAAV Vector Design and Production
The amiR against the mouse ctsk transcript was designed by using a
custom Excel macro, which considers miR-33 scaffold design rules
to generate optimized amiR cassettes.28 DNA sequences for amiR-932 Molecular Therapy: Methods & Clinical Development Vol. 17 June 233-ctrl, amiR-33-rank-1 and -2, and amiR-33-ctsk-1 and -2 were syn-
thesized as gBlocks and cloned into the intronic region of the
pAAVsc-CB6-EGFP plasmid at PstI and BglII restriction enzyme
sites.43 Constructs were verified by Sanger sequencing. Plasmids of
the pAAV-amiR-ctrl, pAAV-amiR-rank-1 and -2, and pAAV-
amiR-ctsk-1 and -2were packaged with AAV9 capsids. rAAV produc-
tion was performed by transient transfection of HEK293 cells, puri-
fied by CsCl sedimentation, and titered by droplet digital PCR
(ddPCR) on a QX200 ddPCR system (Bio-Rad) using the EGFP
primer/probe set as previously described.44 The sequences of gBlocks
and oligonucleotides for ddPCR and are listed in Table S1. The bone-
targeting rAAV9 vectors (AAV9.D14-Nter and AAV9.DSS-Nter)
were generated by inserting the codon-optimized DNA sequence en-
coding the bone-targeting peptide motif, D14 (Asp)14 or DSS (As-
pSerSer)6, into the AAV9 capsid protein VP2, as previously
described.45
Animals
C57BL/6J and BALB/cJ mice were purchased from Jackson Labora-
tory. For systemic delivery, 200 mL of rAAV9 carrying amiR-ctrl,
amiR-rank-1 and -2, or amiR-ctsk-1 and -2 (8  1011 GC/mouse)
was i.v. injected into mice. Mouse models of postmenopausal osteo-
porosis were generated by anesthetizing and bilaterally ovariectomiz-
ing 3-month-old female mice (C57BL/6J). Six weeks after the surgery,
sham or OVXmice were i.v. injected with 200 mL of rAAV9.DSS-Nter
carrying amiR-ctrl or amiR-ctsk (8  1011 GC/mouse). Mice were
randomly divided into three groups with sham + rAAV9.DSS-Nter-
amiR-ctrl, OVX + rAAV9.DSS-Nter-amiR-ctrl, and OVX +
rAAV9.DSS-Nter-amiR-ctsk. As a mouse model of senile osteopo-
rosis, 18-month-old male mice were i.v. injected with 200 mL of
rAAV9.DSS-Nter carrying amiR-ctrl or amiR-ctsk (8  1011 GC/
mouse). All animals were used in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and were handled accord-
ing to protocols approved by the University of Massachusetts Medical
School Institutional Animal Care and Use Committee (IACUC) on
animal care.
MicroCT Analysis
Micro-computed tomography (microCT) was used for qualitative
and quantitative assessment of trabecular and cortical bone micro-
architecture. Analysis was carried out by an investigator blinded to
the genotypes of the animals. Femurs excised from the indicated
mice were fixed with 10% neutral buffered formalin and scanned us-
ing a microCT 35 (Scanco Medical) with a spatial resolution of 7 mm.
For trabecular bone analysis of the distal femur, an upper 2.1-mm re-
gion beginning 280 mm proximal to the growth plate was contoured.
Connectivity density (Conn.D) was calculated with the Conn-Euler
method of Odgaard and Gundersen46 using the Scanco microCT 35
software. Based on a 3D node-and-branch network of a cancellous
bone structure (connectivity), its connectivity density was calculated
by dividing the connectivity estimate by the volume of the sample. For
cortical bone analyses of femurs, midshaft regions of 0.6 mm in length
were used. 3D reconstruction images were obtained from contoured
2D images by methods based on distance transformation of the020
www.moleculartherapy.orgbinarized images. Alternatively, the Inveon multimodality 3D visual-
ization program was used to generate fused 3D viewing of multiple
static or dynamic volumes of microCT modalities (Siemens Medical
Solutions USA). All images presented are representative of the respec-
tive genotypes (n > 6).
Histology, Histomorphometry, and Immunofluorescence
For histological analyses, femurs and tibias were dissected from
rAAV-treated mice, fixed in 10% neutral buffered formalin for
2 days, and decalcified by 5% tetrasodium EDTA for 2–4 weeks. Tis-
sues were dehydrated by passage through an ethanol series, cleared
twice in xylene, embedded in paraffin, and sectioned at a thickness
of 6 mm along the coronal plate from anterior to posterior. Decalcified
femoral sections were stained with TRAP.
For dynamic histomorphometric analysis, 25 mg/kg calcein (Sigma,
C0875) and 50 mg/kg alizarin-3-methyliminodiacetic acid (Sigma,
A3882) dissolved in 2% sodium bicarbonate solution were subcutane-
ously injected into mice in 6-day intervals. MARs and mineralized
surface/BS to calculate BFRs were assessed bymeasuring the distances
between BSs labeled by calcein (existing bone) and alizarin-3-methyl-
iminodiacetic acid (newly formed bone). After fixation in 10% neutral
buffered formalin for 2 days, undecalcified femur samples were
embedded in methyl methacrylate, and the proximal metaphyses of
femurs were sectioned longitudinally (5 mm) and stained with
McNeal’s trichrome for osteoid assessment, toluidine blue for osteo-
blasts, and TRAP for OCs.47 A region of interest was defined in the
trabecular bone of the metaphysis, and BFR/BS, MAR, BS, Ob.S/BS,
and OC surface (Oc.S/BS) were measured using a Nikon Optiphot
2 microscope interfaced with a semiautomatic analysis system
(OsteoMetrics). Measurements were taken on two sections/sample
(separated by ~25 mm) and summed prior to normalization to obtain
a single measure/sample in accordance with the American Society of
Bone and Mineral Research (ASBMR) Histomorphometry Nomen-
clature Committee.48 This methodology has undergone extensive
quality control and validation, and the results were assessed by two
different researchers in a blinded fashion.
For immunofluorescence imaging, fresh femurs dissected from
rAAV-treated mice were collected and immediately fixed in ice-
cold 4% paraformaldehyde solution for 2 days. Semi-decalcification
was carried out for 5 days in 0.5 M EDTA (pH 7.4) at 4C with con-
stant shaking, and infiltration was followed with a mixture of 20% su-
crose in phosphate buffer for 1 day and 25% sucrose in phosphate
buffer the next day. All samples were embedded in a 50/50 mixture
of 25% sucrose solution and OCT compound (Sakura) and cut into
12-mm-thick sagittal sections using a cryostat (Leica). Immunofluo-
rescence staining and analysis were performed as described previ-
ously.47,49 Briefly, after treatment with 0.2% Triton X-100 for
10 min, sections were blocked with 5% donkey serum at room tem-
perature for 30 min and incubated overnight at 4C with anti-
CTSK antibody (A1782, ABclonal, 1:150). Primary antibodies were
visualized with donkey anti-rat IgGAlexa Fluor 594 (1:500,Molecular
Probes). Nuclei were counterstained with DAPI. An Olympus IX81Moleculconfocal microscope or Leica TCS SP5 II Zeiss LSM-880 confocal mi-
croscope was used to image samples.OC and Osteoblast Differentiation Analysis
For OC differentiation, bone marrow cells were flushed from the fe-
murs and tibias of 2-month-old mice (C57BL/6J) and cultured in
Petri dishes in a-minimal essential medium (a-MEM) medium
with 10% fetal bovine serum (FBS) and 20 ng/mL M-CSF (R&D Sys-
tems) to obtain BMMs. 12 h later, nonadherent cells were re-plated
into tissue culture dishes and cultured in the same medium for
2 days. BMMs were then differentiated into OCs in the presence of
RANKL (20 ng/mL; R&D Systems) and M-CSF (20 ng/mL; R&D Sys-
tems) for 6 days. Alternatively, cells were plated into Osteo Assay sur-
face plates (3987, Corning Life Sciences), and OC resorption activity
was measured according to the manufacturer’s instructions.
For osteoblast differentiation, calvarial osteoblasts (COBs) were iso-
lated from 4-day-old mice by enzymatic digestion in a-MEM con-
taining 0.5 mg/mL collagenase-P (Roche) and 0.05% trypsin and
cultured in osteogenic medium (0.1 mg/mL ascorbic acid, 10 mM
b-glycerophosphate). COBs were incubated with 10-fold diluted Ala-
mar Blue solution (Invitrogen, DAL1100) for cell proliferation. Sub-
sequently, cells were washed and incubated with a solution containing
6.5 mM Na2CO3, 18.5 mM NaHCO3, 2 mMMgCl2, and phosphatase
substrate (Sigma, S0942), and alkaline phosphatase activity was
measured by an iMark microplate absorbance reader (Bio-Rad). To
assess extracellular matrix mineralization in mature osteoblasts, cells
were washed twice with phosphate-buffered saline (PBS) and fixed in
70% EtOH for 15 min at room temperature. Fixed cells were washed
twice with distilled water and then stained with a 2% alizarin red so-
lution (Sigma, A5533) for 5 min. Cells were then washed three times
with distilled water and examined for the presence of calcium
deposits.Flow Cytometry
Bone marrow cells were flushed from the femurs and tibias of
2-month-old mice (C57BL/6J) and incubated for 2 min at room tem-
perature with BD Pharm Lyse hypotonic lysis buffer (BioLegend,
420301) for red blood cell (RBC) lysis. Cells were washed twice
with cold fluorescence-activated cell sorting (FACS) buffer, incubated
with Fc blocking buffer (BD Biosciences, 564765) for 15 min at 4C,
and treated with antibody cocktail including CD11b (Tonbo Biosci-
ences, 20-0112), CD45R/B220 (Tonbo Biosciences, 65-0452),
CD117 (Tonbo Biosciences, 60-1172), CD3 (Tonbo Biosciences, 50-
0031), Ter119 (BioLegend, 116233), and Ly6C (BioLegend, 128017)
in cold FACS buffer. After treatment with DAPI, cells were subjected
to FACS analysis using a BD LSR II flow cytometer (BD Biosciences).
The data were analyzed using FlowJo (v.10.1).HA-Binding Assay
HA beads (1 mg/mL) were suspended in 25 mM Tris-HCl (pH 7.4).
Three different GC (108, 109, 1010) of rAAV9, rAAV9.D14-Nter, and
rAAV9.DSS-Nter were incubated with HA in a 100-mL vol for 1 h atar Therapy: Methods & Clinical Development Vol. 17 June 2020 933
Molecular Therapy: Methods & Clinical Development37C and 300 rpm, and then vector titers in the HA pellet and the su-
pernatant were measured by ddPCR.44
ELISA Analysis
CTX1 ELISA (EM0960, FineTest) analysis was performed according
to the manufacturer’s instructions.
Quantitative RT-PCR Analysis
Total RNA was purified from cells using QIAzol (QIAGEN), and
cDNA was synthesized using a high-capacity cDNA reverse tran-
scription kit from Applied Biosystems. Quantitative RT-PCR was
performed using SYBR Green PCR master mix (Bio-Rad) with a
CFX Connect RT-PCR detection system (Bio-Rad). To measure
mRNA levels in bone tissues, tibias were removed of their bone
marrow and snap-frozen in liquid nitrogen for 30 s and homogenized
in 1 mL of QIAzol for 1 min. Primers used for PCR are described in
Table S1.
Statistical Analysis
Except where indicated, all data are graphically represented as the
mean ± SD. For experiments with three or more samples, statistical
analysis was performed using one-way ANOVA followed by a Bon-
ferroni-corrected Student’s t test. For two-sample comparisons, a
two-tailed, unpaired Student’s t test was applied. Values were consid-
ered statistically significant at p <0.05. Results shown are representa-
tive of three or more individual experiments.
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